# Nasal Emulgel’s Role in Preventing Coronavirus Infection

**Authors:** Francesca Accioni, Giovanna Rassu, Antonio Brunetti, Erika Plicanti, Giulia Freer, Antonio Carta, Paolo Giunchedi, Elisabetta Gavini

PMC · DOI: 10.3390/pharmaceutics17060795 · Pharmaceutics · 2025-06-19

## TL;DR

A new nasal emulgel is developed to prevent coronavirus infection by forming a protective barrier in the nasal cavity.

## Contribution

The study introduces a novel, safe, and cost-effective mucoadhesive emulgel for nasal application that inhibits SARS-CoV-2 infection.

## Key findings

- The emulgel with 1.2% HPMC showed optimal mucoadhesion, viscosity, and spreadability for nasal use.
- The emulgel significantly inhibited SARS-CoV-2 infection in epithelial cells in vitro.

## Abstract

Background/Objectives: Coronaviruses (CoVs) are a large family of respiratory viruses that cause respiratory illnesses ranging from mild colds to severe diseases such as severe acute respiratory syndrome and pandemics. The nasal cavity is a primary site for CoV entry and transmission. The study aimed to prepare a novel mucoadhesive emulgel specifically formulated with simple, safe, and cost-effective excipients to create a barrier on the nasal mucosa that impedes CoV infection. This formulation strategy was specifically designed to enable rapid and straightforward in vivo translation, addressing a critical gap in preventive measures against respiratory viruses. Methods: Three emulgels, containing macadamia oil, Carbopol and different percentages of hydroxypropyl methylcellulose (1, 1.2 and 1.5% (w/v), HPMC), were properly prepared and characterized for mucoadhesion, viscosity, and spreadability. The biological activity against SARS-CoV-2 was evaluated in vitro on infected epithelial cells. Results: The emulgel with 1.2% HPMC demonstrated optimal physicochemical properties (mucoadhesion: 342 ± 9 mN/cm2; viscosity: 1080 ± 83 cp; spreadability: 7.27 ± 0.06 cm) suitable for nasal application. Importantly, in vitro biological assays demonstrated that this emulgel significantly inhibits SARS-CoV-2 infection in epithelial cells, indicating an effective barrier to viral diffusion. Conclusions: By employing readily available, safe, and inexpensive excipients, this novel mucoadhesive emulgel offers a practical, scalable, and rapidly translatable nasal prophylactic approach to prevent early SARS-CoV-2 infection, addressing a critical unmet need in pandemic preparedness.

## Linked entities

- **Chemicals:** hydroxypropyl methylcellulose (PubChem CID 57503849)
- **Diseases:** severe acute respiratory syndrome (MONDO:0005091)

## Full-text entities

- **Diseases:** diseases (MESH:D004194), severe acute respiratory syndrome (MESH:D045169), SARS-CoV-2 infection (MESH:D000086382), CoV infection (MESH:D018352), respiratory illnesses (MESH:D012140)
- **Chemicals:** Carbopol (MESH:C006912), HPMC (MESH:D065347), macadamia oil (-)
- **Species:** Coronaviridae (family) [taxon 11118], Hyphomicrobium sp. PMC (species) [taxon 161967], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12197114/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12197114/full.md

## References

55 references — full list in the complete paper: https://tomesphere.com/paper/PMC12197114/full.md

---
Source: https://tomesphere.com/paper/PMC12197114